Use of an oral dpp-4 Inhibitor, which is 1 - (2 - [4 - metilquinazolin - yl) methyl] - 3 - methyl - 4 - (2 - BUTYN - 1 - 8 (IL -) - 3 - (R) - amino - piperidin-1-yl) xanthine, in an amount of 1 to 10 mg, and metformin for preparing a Pharmaceutical composition useful for improving Glycemic Control in patients with Type 2 diabetes.
Compound dpp-4 inhibitor； useful to improve glycaemic control in patients with Type 2 diabetes, glycosylated hemoglobin and / or reduce plasma glucose in fasted patients.<；p>；Compuesto inhibidor de dpp-4； ú；til para mejorar el control glucé；mico en pacientes con diabetes tipo 2, para reducir la hemoglobina glucosilada y/o la glucosa plasmá；tica en pacientes en ayunas.<；/p>；
